Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

462 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The "Parkinsonian heart": from novel vistas to advanced therapeutic approaches in Parkinson's disease.
Fornai F, Ruffoli R, Soldani P, Ruggieri S, Paparelli A. Fornai F, et al. Curr Med Chem. 2007;14(23):2421-8. doi: 10.2174/092986707782023631. Curr Med Chem. 2007. PMID: 17979697 Review.
The present manuscript reviews novel data on the progressive involvement of different regions of the central nervous system as well as peripheral nerves in Parkinson's disease. ...These effects recently became a major issue and led to consider all ergot dopamine agonists a …
The present manuscript reviews novel data on the progressive involvement of different regions of the central nervous system as well as perip …
Re-defining Parkinson's disease.
Fornai F, Ruggieri S. Fornai F, et al. Arch Ital Biol. 2013 Dec;151(4):137-42. Arch Ital Biol. 2013. PMID: 24873922
Analyzing non-motor symptoms in Parkinson's disease (PD) leads to critically re-define and update the disorder itself. The present Editorial encompasses epidemiological and clinical studies on PD patients joined with experimental findings to provide a novel definition of P …
Analyzing non-motor symptoms in Parkinson's disease (PD) leads to critically re-define and update the disorder itself. The present Ed …
A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease.
Bonuccelli U, Meco G, Fabbrini G, Tessitore A, Pierantozzi M, Stocchi F, Ceravolo R, Caltagirone C, Silvestrini M, Morgante F, Ruggieri S, Avanzino L, Guadagna M, Dell'Agnello G, Rossi A, Spezia R, Mancini M. Bonuccelli U, et al. Expert Opin Pharmacother. 2012 Nov;13(16):2269-80. doi: 10.1517/14656566.2012.736490. Expert Opin Pharmacother. 2012. PMID: 23067321 Clinical Trial.
OBJECTIVE: Depression is a comorbidity affecting quality of life (QoL) in patients with Parkinson's disease (PD) and requires appropriate treatment. ...Efficacy measures included HAMD-17, BDI, CGI-S, PGI-I, and pain VAS. QoL was measured by PDQ-39. RESULTS: Of the 1 …
OBJECTIVE: Depression is a comorbidity affecting quality of life (QoL) in patients with Parkinson's disease (PD) and requires appropr …
Does autophagy worsen or improve the survival of dopaminergic neurons?
Pasquali L, Ruggieri S, Murri L, Paparelli A, Fornai F. Pasquali L, et al. Parkinsonism Relat Disord. 2009 Dec;15 Suppl 4:S24-7. doi: 10.1016/S1353-8020(09)70830-2. Parkinsonism Relat Disord. 2009. PMID: 20123552 Review.
With respect to dopaminergic neurons, there is evidence that autophagy occurs during damage to substantia nigra neurons such as in Parkinson's disease. Moreover, a variety of inherited forms of Parkinson's disease are characterized by mutated proteins that belong to …
With respect to dopaminergic neurons, there is evidence that autophagy occurs during damage to substantia nigra neurons such as in Parkinson …
MPTP-induced parkinsonism extends to a subclass of TH-positive neurons in the gut.
Natale G, Kastsiushenka O, Fulceri F, Ruggieri S, Paparelli A, Fornai F. Natale G, et al. Brain Res. 2010 Oct 8;1355:195-206. doi: 10.1016/j.brainres.2010.07.076. Epub 2010 Aug 5. Brain Res. 2010. PMID: 20691673
Gastrointestinal (GI) dysfunction occurs frequently in early Parkinson's disease (PD) and it is supposed to anticipate motor symptoms. ...
Gastrointestinal (GI) dysfunction occurs frequently in early Parkinson's disease (PD) and it is supposed to anticipate motor symptoms …
Convergent roles of alpha-synuclein, DA metabolism, and the ubiquitin-proteasome system in nigrostriatal toxicity.
Fornai F, Lazzeri G, Bandettini Di Poggio A, Soldani P, De Blasi A, Nicoletti F, Ruggieri S, Paparelli A. Fornai F, et al. Ann N Y Acad Sci. 2006 Aug;1074:84-9. doi: 10.1196/annals.1369.007. Ann N Y Acad Sci. 2006. PMID: 17105905
Recent studies disclosed the relevance of specific molecules for the onset of Parkinson's disease (PD) and for the composition of neuronal inclusions. ...
Recent studies disclosed the relevance of specific molecules for the onset of Parkinson's disease (PD) and for the composition of neu …
Is there a role for uridine and pyrimidine nucleosides in the treatment of vascular dementia?
Fornai F, Busceti CL, Ferrucci M, Lazzeri G, Ruggieri S. Fornai F, et al. Funct Neurol. 2002 Apr-Jun;17(2):93-9. Funct Neurol. 2002. PMID: 12224797 Review.
The possibility that loss of a given neurotransmitter might be associated with the onset of a specific neurological syndrome led to suggestions that, as had already been found in Parkinson's disease, replacement therapy might drastically improve the course of the syndrome. …
The possibility that loss of a given neurotransmitter might be associated with the onset of a specific neurological syndrome led to suggesti …
Dual dopamine agonist treatment in Parkinson's disease.
Stocchi F, Vacca L, Berardelli A, Onofrj M, Manfredi M, Ruggieri S. Stocchi F, et al. J Neurol. 2003 Jul;250(7):822-6. doi: 10.1007/s00415-003-1086-0. J Neurol. 2003. PMID: 12883924
We studied the effectiveness of cabergoline as an adjunct in patients with early Parkinson's disease receiving another dopamine agonist (pramipexole or ropinirole), at the maximal permitted dose. ...This open study shows that dual dopamine agonist therapy can be useful in …
We studied the effectiveness of cabergoline as an adjunct in patients with early Parkinson's disease receiving another dopamine agoni …
Intermittent Dopaminergic stimulation causes behavioral sensitization in the addicted brain and parkinsonism.
Fornai F, Biagioni F, Fulceri F, Murri L, Ruggieri S, Paparelli A. Fornai F, et al. Int Rev Neurobiol. 2009;88:371-98. doi: 10.1016/S0074-7742(09)88013-6. Int Rev Neurobiol. 2009. PMID: 19897084 Review.
The gold standard therapy for Parkinson's disease (PD) consists in chronic administration of pulses of the dopamine (DA) precursor l-dihydroxyphenylalanine (l-DOPA). ...
The gold standard therapy for Parkinson's disease (PD) consists in chronic administration of pulses of the dopamine (DA) precursor l- …
MPTP- but not methamphetamine-induced parkinsonism extends to catecholamine neurons in the gut.
Natale G, Kastsiuchenka O, Pasquali L, Ruggieri S, Paparelli A, Fornai F. Natale G, et al. Ann N Y Acad Sci. 2008 Oct;1139:345-9. doi: 10.1196/annals.1432.015. Ann N Y Acad Sci. 2008. PMID: 18991880
Methamphetamine (METH) produces nigrostriatal dopamine (DA) loss, partly resembling that which occurs in Parkinson's disease (PD). ...
Methamphetamine (METH) produces nigrostriatal dopamine (DA) loss, partly resembling that which occurs in Parkinson's disease (PD). .. …
462 results
Jump to page
Feedback